Shattuck Labs Announces Participation in Upcoming March Conferences

Rhea-AI Summary

Shattuck Labs, Inc. (STTK) announced participation in investor conferences to discuss the development of bi-functional fusion proteins for cancer and autoimmune disease treatment. Key conferences include TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference 2024, and Citi's Biotech C-Suite Fireside Chat Series.

AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in multiple investor conferences in March 2024.

Presentation Details
Conference: TD Cowen 44th Annual Health Care Conference
Format: Panel Discussion and 1x1 Meetings
Panel Topic: Novel IO Corporate Panel Discussion

• Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
• Date: March 4, 2024
• Time: 10:30-11:30 a.m. ET
  

Conference: Leerink Partners Global Biopharma Conference 2024
Format: 1x1 Meetings
Dates: March 11-12, 2024

Conference: Citi's Biotech C-Suite Fireside Chat Series
Format: Fireside chat with covering analyst Yigal Nochomovitz, Ph.D.

• Presenters: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, M.B.A., Shattuck’s Chief Financial Officer
• Date: March 20, 2024
• Time: 11:00 a.m. ET
  

A live webcast of the presentations will be available on the Investors section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, (“ARC®”), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

FAQ

When will Shattuck Labs participate in the TD Cowen 44th Annual Health Care Conference?

Shattuck Labs will participate in the TD Cowen 44th Annual Health Care Conference on March 4, 2024.

Who will be the presenter at the Novel IO Corporate Panel Discussion?

Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer, will be the presenter at the Novel IO Corporate Panel Discussion.

What is the format of the Leerink Partners Global Biopharma Conference 2024?

The Leerink Partners Global Biopharma Conference 2024 will have 1x1 Meetings on March 11-12, 2024.

Who are the presenters at Citi's Biotech C-Suite Fireside Chat Series?

Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer, and Andrew Neill, M.B.A., Shattuck’s Chief Financial Officer, will be the presenters at Citi's Biotech C-Suite Fireside Chat Series.

Where can the live webcast of the presentations be accessed?

The live webcast of the presentations will be available on the Investors section of Shattuck Labs' website.

How long will the replay of the webcast be archived?

The replay of the webcast will be archived for up to 30 days following the presentation date.